Matthew Gdovin, PhD

Founder & Chief Science Officer

Therapeutic Areas

Drug	Indication	Phase
LUXVIVO	Canine Melanoma	Veterinary INAD-stage
LAIA Platform	Human Solid Tumors	Research/Preclinical